Apparently, no agonist has been found that is comparable in potency to the luteinizing hormone-releasing hormone (LHRH) for release of LH and follicle-stimulating hormone (FSH) without substitutions with unnatural or D forms of natural amino acids. Of 139 known "agonist analogs" of LHRH, two were active in the range of 65%. The four LHRHs known to occur in nature involve a total of six amino acids (Tyr, His, Leu, Trp, Arg, Gln) in positions 5, 7, and 8. There are 16 possible peptides with these six amino acids in positions 5, 7, and 8, of which 4 are the known LHRHs, and 2 more were synthesized. We have synthesized the 10 new peptides and assayed 11 in vivo and in vitro, and we found not only 1 but a total of 5 that have activity equivalent to or greater than that of LHRH for the release of LH and/or FSH under at least one assay condition. The four naturally occurring LHRHs are as follows:
Since the elucidation of the structure of the luteinizing hormone-releasing hormone (LHRH) (2) was reported to have 80% activity in vivo. Two analogs, both of which contain an unnatural amino acid, were apparently equal to or more potent than LHRH. They were [3(2- The four naturally occurring LHRHs are as follows:
pGlu'-His2-Trp3-Ser4-His5-Gly6-Trp7-Tyr8-Pro9-Gly'0-NH2. (i) With only one substitution in LHRH:
1. pGlu-His-Tr-p-Ser-His-Gly-Leu-Arg-Pro-Gly-NH2
2. pGlu-His-Trp-Ser-Tyr-Gly-Trp-Arg-Pro-Gly-NH2 3. pGlu-His-Trp-Ser-Tyr-Gly-Leu-Leu-Pro-Gly-NH2 4. pGlu-His-Trp-Ser-Tyr-Gly-Leu-Tyr-Pro-Gly-NH2.
(ii) With two substitutions in LHRH:
5. pGlu-His-Trp-Ser-His-Gly-Leu-Leu-Pro-Gly-NH2 6. pGlu-His-Trp-Ser-His-Gly-Leu-Tyr-Pro-Gly-NH2 7. pGlu-His-Trp-Ser-His-Gly-Leu-Gln-Pro-Gly-NH2 8. pGlu-His-Trp-Ser-Tyr-Gly-Trp-Tyr-Pro-Gly-NH2
9. pGlu-His-Tr-p-Ser-Tyr-Gly-Trp-Gln-Pro-Gly-NH2
10. pGlu-His-Trp-Ser-His-Gly-Trp-Arg-Pro-Gly-NH2.
(iii) With three substitutions in LHRH:
11. pGlu-His-Trp-Ser-His-Gly-Trp-Leu-Pro-Gly-NH2 12. pGlu-His-Trp-Ser-His-Gly-Trp-Gln-Pro-Gly-NH2.
Two of these 12 peptides are known: number 2 was described by Cone et al. (2) and number 3 was described by Yanaihara et al. (7) .
The remaining 10 synthesizer, the cleavage of the peptides from the resin, the column chromatography on silica gel, the preparative HPLC purification, the determination of purity and the characterization, and the amino acid analyses were conducted essentially as described (8) . The assays in 26-day-old immature female rats were conducted as described (9) . In brief, the peptides were administered sxc. and blood was collected for the radioimmunoassay of LH and FSH.
The data on the retention times of the peptides by HPLC are in Table 1 , the data from the thin-layer chromatography are in Table 2 , and the data from the amino acid analyses are in Table 3 .
Chemical Results and Hormonal Activities in Vivo in Rats. The activities of the four natural LHRHs are shown in Table   4 All hydrolyses were performed in evacuated sealed tubes with 6 M HCI at 110TC for 24 hr. Peptides 12 and 13 were purchased from Peninsula Laboratories. These are the data given by Peninsula for peptides 12 and 13. that revealed a potency equal to or greater than that of LHRH. The bioassay data on the remaining six peptides reveal potencies significantly less than that of LHRH. For brevity, these latter assay data will be reported in subsequent publications with ongoing extensions of the chemistry and biology of these six peptides. The The data in Table 5 on the peptides with three structural modifications revealed that at dosage levels of 300 ng and 3000 ng, [His5,Trp7,Gln8]LHRH released less LH, but as much FSH as LHRH at the higher dosage of 3000 ng, when It is plausible that one or more of these five agonists can be modified to achieve other classes ofantagonists. Of particular importance may be antagonists with Gln8 and Leu in place of Arg8 of LHRH, which might provide antagonists without the side effect of histamine release.
Nomenclature. The four peptides with a His5 moiety, in particular, may become widely investigated and a simple and self-evident nomenclature may be useful. Therefore, the word "histide," from histidine and peptide, combined with the conventional letter in amino acid nomenclature for the moieties in positions 7 assay of the [His5,Trp7,Gln8]LHRH, this peptide has almost the same LH and FSH releasing activity as LHRH. These data also support the possibility that different receptors (subtypes) may be involved, and uniquely discordant effects on LH/FSH may be induced by these decapeptides, which may function at the same time in more than one receptor.
Another major point is that the relative effects on LH and FSH release are dose and time dependent. From this view- 
